Seevividly

Market position

The company positions itself as a provider of digital vision care tools that can substitute for or supplement in-clinic equipment, claiming Vivid Vision Perimetry delivers 6.8x better precision than standard automated perimetry and matches in-clinic microperimetry accuracy when used at home. It cites use by large ophthalmic pharmaceutical companies and validation of targeted microperimetry as an endpoint in early-phase trials, alongside supportive statements from researchers at Duke University Medical Center and the Retina Foundation of the Southwest.

Vivid Vision's perimetry approach allows natural fixation and free eye movement with per-trial feedback and optional guessing, aiming to make testing less fatiguing than conventional perimetry, which requires bulky equipment and a skilled perimetrist. The company reports 6.8x better precision than standard automated perimetry, 2x better fixation stability and 99% adherence to at-home testing, and the ability to collect far more visual field data points per year at home on low-cost VR hardware.

Technology

The platform runs on standard commercially available VR head-mounted displays and interoperates with third-party applications such as Oculus and Steam VR. Therapy modules use dichoptic game-like activities and virtual prism settings; the diagnostic side includes VR implementations of clinical tests (Prism Tuner using dissociated Maddox-rod-style and associated prism trials, vergence range and facility, stereoacuity, deviation at 600/200/40 cm) and Vivid Vision Perimetry, which permits natural fixation and free eye movement rather than the enforced fixation of conventional perimetry. The company cites expertise in psychophysics, VR game software engineering, HIPAA-compliant telemedicine and IP protection, and has added account login and HIPAA-oriented data protection features to the clinical software.

Go-to-market

Distribution runs through eye care providers and authorized distributors, supported by an online doctor locator that routes patients to certified Vivid Vision Providers. The company markets through its blog, newsletters, podcasts and provider spotlights, conference presence, and partnership outreach to pharmaceutical sponsors for clinical trial endpoint use.

Optometrists, ophthalmologists and vision therapy clinics; patients prescribed home VR therapy by those providers; and pharmaceutical companies and research institutions running clinical trials in geographic atrophy, AMD and glaucoma.

Geography

Headquartered in San Francisco, California, with reported patient use across more than 50 countries and localized software in English, German, Japanese, Chinese (Simplified), Slovak and Portuguese. Blog tagging references activity in Europe, Central Europe, Asia, Australia, Mexico, Canada and the United States.

History

The website states the product has been in use since 2014, and the 2023 NIH award abstract describes Vivid Vision, Inc. as a seven-year-old San Francisco company. Early products and branding referenced in company materials include Diplopia and Apollo VR. In May 2017 the company announced a financing and partnership with SoftTech VC, The VR Fund, Liquid 2 Ventures and others to accelerate its VR vision care platform. The product line later expanded from binocular vision therapy into visual field testing with Vivid Vision Perimetry and VVP-10, and into clinical trial endpoint services.

Risks & controversies

The NIH award abstract notes high variability in conventional visual field results and the technical challenge of optimizing data quality, with the Phase II project still required to verify that VVP-10 halves the time needed to detect rapid progression. The platform depends on third-party VR ecosystems such as Oculus and Steam VR that the company does not control, and it processes health and personal data subject to HIPAA and EU privacy laws.